BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Advanced Neuroscience Research

Executive Summary: BIIE 0246 is a highly selective antagonist of the neuropeptide Y Y2 receptor (Y2R), with an IC50 of 3.3 nM and Ki values between 8–15 nM, enabling the precise inhibition of NPY-mediated presynaptic effects in rodent models (APExBIO). It fully blocks PYY3-36-induced contractions in rat colon and attenuates PYY(3-36)-induced feeding reduction, supporting its utility in satiety and metabolic research (Fan et al., 2024). BIIE 0246 displays anxiolytic-like effects in the elevated plus-maze, confirming its engagement with central nervous system Y2R signaling. The compound's robust solubility profile (up to 67.2 mg/ml in DMSO) and validated workflow integration make it a cornerstone tool for dissecting neuropeptide Y signaling and the adipose-neural axis. This article synthesizes mechanistic, methodological, and translational insights, updating and extending prior usage guides (BIIE 0246: Enhancing Y2R Antagonist Assays).

Biological Rationale

The neuropeptide Y (NPY) system is a critical regulator of energy homeostasis, anxiety, feeding behavior, and cardiovascular function. Y2 receptors (Y2R) are G-protein-coupled receptors distributed in both the central and peripheral nervous systems (Fan et al., 2024). Y2R is primarily presynaptic and acts as an inhibitory autoreceptor, regulating NPY and other neurotransmitter release. Recent findings implicate the adipose-neural axis—particularly NPY/Y receptor signaling—in metabolic and cardiac pathophysiology, such as arrhythmias associated with epicardial adipose tissue (EAT) (Fan et al., 2024). Thus, selective Y2R antagonists like BIIE 0246 enable targeted dissection of neural, metabolic, and cardiovascular circuits by modulating presynaptic inhibition and downstream physiological outcomes (Advanced Dissection of Y2R Antagonism—this article provides updated mechanistic context and translational benchmarks).

Mechanism of Action of BIIE 0246

BIIE 0246 acts as a potent, selective antagonist of the NPY Y2 receptor. In competitive binding assays, BIIE 0246 exhibits an IC50 of 3.3 nM and Ki values between 8–15 nM for PYY3-36 binding sites, reflecting nanomolar affinity and high selectivity over other NPY receptor subtypes (APExBIO). By blocking Y2R, BIIE 0246 suppresses NPY-induced presynaptic inhibition, as shown by its ability to prevent NPY-mediated decreases in primary afterdischarge activity and population excitatory postsynaptic potentials in rat hippocampal slices. This blockade leads to increased neurotransmitter release and altered synaptic plasticity. In peripheral models, BIIE 0246 fully inhibits PYY3-36-induced colonic contraction, confirming Y2R specificity. In vivo, it attenuates PYY(3-36)-induced reduction in food intake, demonstrating a critical role in satiety signaling (Fan et al., 2024).

Evidence & Benchmarks

• BIIE 0246 exhibits nanomolar affinity (IC50 = 3.3 nM; Ki = 8–15 nM) for the NPY Y2 receptor, with high selectivity over Y1 and Y5 subtypes (APExBIO).
• Blocks NPY-induced presynaptic inhibition in rat hippocampal neurons, restoring afterdischarge and postsynaptic potential amplitudes (Fan et al., 2024, Table 1).
• Completely inhibits PYY3-36-induced contraction in ex vivo rat colon models, confirming peripheral Y2R antagonism (Fan et al., 2024, Fig. 3).
• Attenuates PYY(3-36)-induced reduction of food intake in rats, supporting roles in post-prandial satiety pathways (Fan et al., 2024, Suppl. Data).
• Produces anxiolytic-like effects in the elevated plus-maze, indicating central Y2R engagement (Selective Neuropeptide Y Y2 Receptor Antagonist—this article cross-validates behavioral endpoints and workflow integration).
• Recommended solubility: up to 67.2 mg/ml in DMSO and 23.55 mg/ml in ethanol; stable at 4°C, but long-term solutions are not advised (APExBIO).

Applications, Limits & Misconceptions

BIIE 0246 is validated for applications in central and peripheral models of NPY/Y2R signaling. It is widely used in studies on feeding behavior, satiety, anxiety, and synaptic transmission. Its selectivity enables robust dissection of presynaptic inhibition and adipose-neural axis dynamics, including arrhythmia pathogenesis (Fan et al., 2024; Unraveling the Adipose-Neural Axis—this article updates translational applications in cardiac and metabolic research).

Common Pitfalls or Misconceptions

• BIIE 0246 is strictly a research tool and is not approved for clinical, diagnostic, or therapeutic use (APExBIO).
• It does not antagonize Y1 or Y5 receptors at recommended concentrations; off-target effects are rare but possible at high doses.
• Long-term storage of prepared solutions (over weeks) leads to potency loss; always prepare fresh aliquots for critical assays.
• BIIE 0246 does not inhibit leptin or Y1 receptor signaling, which are also implicated in the adipose-neural axis (Fan et al., 2024).
• Behavioral effects (e.g., anxiolytic-like) require central administration; peripheral dosing alone may not recapitulate CNS outcomes.

Workflow Integration & Parameters

BIIE 0246 is supplied by APExBIO as a white solid (SKU B6836; MW 896.06; C₄₉H₅₇N₁₁O₆). For in vitro studies, dissolve in DMSO (up to 67.2 mg/ml) or ethanol (23.55 mg/ml). Store powder at 4°C. Avoid repeated freeze-thaw cycles. Dose selection should be based on target tissue, administration route, and model organism; effective concentrations range from 10 nM (cellular) to 1 mg/kg (in vivo, i.p. or i.c.v.) (APExBIO). For detailed workflow optimization in cytotoxicity and viability assays, see BIIE 0246: Enhancing Y2R Antagonist Assays—this article provides expanded context on advanced cardiovascular and satiety applications.

Conclusion & Outlook

BIIE 0246 remains the benchmark selective Y2R antagonist for neuroscience, metabolic, and cardiovascular research. Its nanomolar potency, selectivity, and translational validation in feeding, anxiety, and arrhythmia models underscore its essential role in dissecting NPY/Y2R pathways. Ongoing research into the adipose-neural axis and related disorders highlights BIIE 0246's value for future mechanistic discovery and drug development. For ordering and technical documentation, refer to the BIIE 0246 product page at APExBIO.